TITLE

Safety of Inhaled Budesonide

AUTHOR(S)
Christensson, Camilla; Thorén, Anders; Lindberg, Bengt
PUB. DATE
August 2008
SOURCE
Drug Safety;2008, Vol. 31 Issue 11, p965
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Inhaled corticosteroid (ICS) therapy is central to the long-term management of asthma and is extensively used in the management of chronic obstructive pulmonary disease (COPD). While administration via inhalation limits systemic exposure compared with oral or injected corticosteroids and, therefore, the risk of systemic corticosteroid-related adverse effects, concerns over the long-term safety of ICS persist. The assessment of the long-term effects of ICS therapy requires considerable research effort over years or even decades, Surrogate markers/predictors for clinical endpoints such as adrenal crisis, reduced final height and fractures have been identified for use in relatively short-term studies. However, the predictive value of such markers remains questionable. Inhaled budesonide has been available since the early 1980s and there is a considerable evidence base investigating the safety of this agent. To assess the long-term safety of inhaled budesonide therapy in terms of the actual incidence of the clinical endpoints adrenal crisis/insufficiency, reduced final height, fractures and pregnancy complications, we undertook a review of the scientific literature. The external databases BIOSIS, Cochrane Central Register of Controlled Trials. Current Contents, EMBASE, International Pharmaceutical Abstracts and MEDLINE were searched, in addition to AstraZeneca's internal product literature database Planet, up to 29 February 2008. Only original articles of epidemiological studies, national surveys, clinical trials and case reports concerning inhaled budesonide were included. Eight surveys of adrenal crisis were found. The only survey with specified criteria for diagnosis involved 2912 paediatricians and endocrinologists and revealed 33 patients with adrenal crisis associated with ICS therapy: only one patient used budesonide (in co-treatment with fluticasone propionate). In addition, 14 case reports of adrenal crisis in budesonide-treated patients were found. In only two of these, budesonide was used at recommended doses and in the absence of interacting medication. Three retrospective studies and one prospective study assessing final height were found. None of them showed any reduced final height in patients receiving inhaled budesonide during childhood or adolescence. Seventeen epidemiological studies investigating the risk of fractures were found. When adjusting for confounding factors, they did not provide any unequivocal data for an increased fracture risk with budesonide. Four prospective placebo-controlled clinical trials of 2-6 years duration with inhaled budesonide in patients with asthma or COPD were found. None of the studies identified any association between inhaled budesonide and increased risk for fractures. Four studies using data from the Swedish birth and health registries showed there was no increased risk for congenital malformations, cardiovascular defects, decreased gestational age, birth weight or birth length among Infants born to women using inhaled budesonide during pregnancy compared with the general population. This was confirmed by five observational studies in Australia, Canada. Hungary, Japan and the US. Similarly, one randomized clinical trial comparing pregnancy outcomes among asthma patients receiving inhaled budesonide or placebo did not demonstrate any difference in outcome of pregnancy. In summary, based on 25 years of experience with different doses and in different populations, inhaled budesonide therapy only in very rare cases appears to be associated with an increased risk of adrenal crisis, reduction in final height, increases in the number of fractures or complications during pregnancy.
ACCESSION #
37704942

 

Related Articles

  • Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in COPD. Rees, P. John // Evidence Based Medicine;Jun2009, Vol. 14 Issue 3, p8 

    The article offers information on the advantages and disadvantages of inhaled corticosteroid (ICS) therapy in treating patients with stable chronic obstructive pulmonary disease (COPD). It notes that inhaled cortecosteroids with placebo or inhaled medications can contribute to mortality,...

  • Analysis. Summerton, Nick // Update;5/19/2005, Vol. 70 Issue 5, p26 

    This article presents a study to find out whether intermittent as-needed corticosteroid treatment for mild persistent asthma equivalent to regular daily treatment. Treatment with daily or intermittent corticosteroid therapy in a six-centre randomised controlled trial was conducted. After...

  • Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Harrison, T. W.; Wisniewski, A.; Honour, J.; Tattersfield, A. B. // Thorax;Mar2001, Vol. 56 Issue 3, p186 

    Background-The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fiuticasone propionate and budesonide have been compared in this way the results have been inconsistent. To...

  • Mild persistent asthma and inhaled corticosteroids: is daily therapy really necessary? Bauchner, Howard // Archives of Disease in Childhood;Oct2005, Vol. 90 Issue 10, p1094 

    This article cites a study on the treatment of mild persistent asthma, which was published in the May 6, 2005 issue of the "Journal Watch Pediatrics and Adolescent Medicine." In this double-blind trial, researchers randomized 225 adults with mild persistent asthma to receive twice-daily inhaled...

  • Daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p60 

    This article presents information on a clinical study according to which daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma. This study explored that in patients with mild persistent asthma, how does intermittent, short-course corticosteroid treatment...

  • Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Sin, D. D.; Wu, L.; Anderson, J. A.; Anthonisen, N. R.; Buist, A. S.; Burge, P. S.; Calverley, P. M.; Connett, J. E.; Lindmark, B.; Pauwels, R. A.; Postma, D. S.; Soriano, J. B.; Szafranski, W.; Vestbo, J. // Thorax;Dec2005, Vol. 60 Issue 12, p992 

    Background: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in chronic obstructive pulmonary disease (COPD). However, their effect on mortality is unknown. Methods: A pooled analysis, based on intention to treat, of individual patient data...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

  • Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People. Hubbard, Richard; Tattersfield, Anne // Drugs & Aging;2004, Vol. 21 Issue 10, p631 

    The efficacy of inhaled corticosteroids in the treatment of asthma has been firmly established in a variety of settings. The majority of asthma management plans now recommend the use of inhaled corticosteroids at an early stage. This means that most patients with asthma will be prescribed an...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics